AbbVie (ABBV)
(Delayed Data from NYSE)
$193.47 USD
-0.15 (-0.08%)
Updated Sep 20, 2024 04:02 PM ET
After-Market: $193.31 -0.16 (-0.08%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Company Summary
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal has transformed AbbVie’s portfolio by lowering its dependence on Humira, its flagship product, which has lost patent protection in Europe as well as the United States. Its newest immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories divested its pharmaceutical division. In May 2020, AbbVie acquired Allergan for about $20 billion. In June 2016, ...
Company Summary
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal has transformed AbbVie’s portfolio by lowering its dependence on Humira, its flagship product, which has lost patent protection in Europe as well as the United States. Its newest immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories divested its pharmaceutical division. In May 2020, AbbVie acquired Allergan for about $20 billion. In June 2016, AbbVie acquired cancer drugmaker, Stemcentrx in a cash-and-stock deal worth $5.8 billion. In February 2023, AbbVie acquired ImmunoGen which added the latter’s antibody-drug conjugate (ADC) for ovaria cancer, Elahere to AbbVie’s oncology portfolio.
AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics and eye care.
Humira is approved for several autoimmune diseases like rheumatoid arthritis (RA), active psoriatic arthritis, active ankylosing spondylitis, Crohn’s disease and others. Imbruvica (hematological cancers) became part of the company’s portfolio following the Pharmacyclics acquisition.
Other key drugs include Venclexta (venetoclax) (hematological malignancies), Botox Cosmetic (aesthetic use), Botox Therapeutics (neuroscience indications), Vraylar (schizophrenia and bipolar I disorder), Skyrizi (plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease) and Rinvoq (RA, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, Crohn’s disease and ulcerative colitis). The company also has partnerships with companies like Roche and J&J.
AbbVie reported total sales of $54.3 billion for 2023, down 6.4% on a reported basis and 5.9% on an operational basis. Humira, Skyrizi and Rinvoq accounted for 26.5%, 14.3% and 7.3%, respectively, of AbbVie’s total revenues in 2023. Imbruvica accounted for 6.6%, while Botox (cosmetic and therapeutic) accounted for 10.4% of AbbVie’s total revenues in 2023.
General Information
AbbVie Inc
1 NORTH WAUKEGAN ROAD
NORTH CHICAGO, IL 60064
Phone: 847-932-7900
Fax: 302-655-5049
Email: NA
Industry | Large Cap Pharmaceuticals |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 10/25/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 2.95 |
Current Year EPS Consensus Estimate | 10.87 |
Estimated Long-Term EPS Growth Rate | 6.70 |
Exp Earnings Date | 10/25/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 193.62 |
52 Week High | 199.95 |
52 Week Low | 135.85 |
Beta | 0.64 |
20 Day Moving Average | 4,279,458.00 |
Target Price Consensus | 198.09 |
4 Week | -2.07 |
12 Week | 12.80 |
YTD | 24.84 |
4 Week | -3.23 |
12 Week | 8.01 |
YTD | 4.42 |
Shares Outstanding (millions) | 1,766.34 |
Market Capitalization (millions) | 341,734.53 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 3.20% |
Annual Dividend | $6.20 |
Payout Ratio | 0.58 |
Change in Payout Ratio | 0.11 |
Last Dividend Payout / Amount | 7/15/2024 / $1.55 |
Fundamental Ratios
P/E (F1) | 17.80 |
Trailing 12 Months | 18.08 |
PEG Ratio | 2.64 |
vs. Previous Year | -8.93% |
vs. Previous Quarter | 14.72% |
vs. Previous Year | 4.31% |
vs. Previous Quarter | 17.48% |
Price/Book | 50.10 |
Price/Cash Flow | 12.23 |
Price / Sales | 6.21 |
6/30/24 | 203.66 |
3/31/24 | 179.47 |
12/31/23 | 162.28 |
6/30/24 | 13.56 |
3/31/24 | 14.05 |
12/31/23 | 14.62 |
6/30/24 | 0.81 |
3/31/24 | 0.94 |
12/31/23 | 0.87 |
6/30/24 | 0.71 |
3/31/24 | 0.83 |
12/31/23 | 0.76 |
6/30/24 | 34.62 |
3/31/24 | 35.85 |
12/31/23 | 36.40 |
6/30/24 | 9.71 |
3/31/24 | 11.02 |
12/31/23 | 8.95 |
6/30/24 | 12.85 |
3/31/24 | 13.84 |
12/31/23 | 11.51 |
6/30/24 | 3.86 |
3/31/24 | 4.56 |
12/31/23 | 5.78 |
6/30/24 | 4.95 |
3/31/24 | 5.01 |
12/31/23 | 5.11 |
6/30/24 | 8.51 |
3/31/24 | 7.93 |
12/31/23 | 5.02 |
6/30/24 | 89.49 |
3/31/24 | 88.80 |
12/31/23 | 83.39 |